title: A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature.
abstract: In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.
authors.affiliation: Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada. Electronic address: kkhan@sri.utoronto.ca.
authors.forename: Kabir A
authors.initials: KA
authors.lastname: Khan
authors.affiliation: Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kerbel
mesh_terms: D000906:Antibodies; D045744:Cell Line, Tumor; D006801:Humans; D018796:Immunoconjugates
chemical_list: D000906:Antibodies; D018796:Immunoconjugates